INITIAL EXPERIENCE WITH THE OXYTOCIN ANTAGONIST ATOSIBAN FOR PRETERM LABOR IN A TERTIARY CARE CENTRE: PROSPECTIVE OBSERVATIONAL COHORT STUDY
*Bhatt Reema K., Dr. Anupam Kapur, Dr. Shikha Choudhary, Dr. Sanjay Sharma and Dr. Pranjali Dwivewdi
ABSTRACT
Background: Preterm labor(PTL) leads to alarming situations and challenges for doctors and is a distressing
condition for pregnant women and their families. Therapy with uterospecific tocolytic Atosiban is a common
practice nowadays due its high efficacy and safety evidences in inhibiting the early uterine contractions thus
delaying the delivery, permitting better fetal growth and reducing the newborn mortality and morbidity. Aims: To
evaluate efficacy and safety of uterospecific tocolytic Atosiban in pregnant women with PTL. Settings and
Design: Prospective observational cohort study was conducted in the Department of Obstetrics and Gynecology,
Tertiary Care Hospital, North India. Methods and Material: 150 singleton/twin pregnant women were
administered Atosiban intravenously for 48 hours. Efficacy was determined by the percentage of women who
remained undelivered after therapy initiation up to 48 hours. Safety was assessed by the numbers of maternal, fetal
or neonatal adverse events (AE) reported. Statistical analysis used: Intent-to-treat statistical analysis was used.
Descriptive statistics were used to represent the data [expressed as Mean ± SD, N (%)]. Results: Atosiban
successfully delayed the preterm deliveries by ≥ 48 hours in 146 (97.3 %) pregnant women, of which 140
pregnancies remained undelivered for ˃7 days and some of them even up to 5 weeks. No maternal and fetal AE
were reported, 01 neonatal death occurred due to sepsis. Conclusion: Based on our initial clinical experience, we
conclude that Atosiban is an effective and well tolerated drug in prolonging the duration of pregnancy in women
with PTL.
Keywords: Atosiban, Gestation, Labor, Oxytocin, Pregnant, Preterm, Prolongation, Tocolytic.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
